Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Old API Wind-down Ltd - Ordinary Shares ARLZQ

"Old API Wind-down Ltd, formerly Aralez Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in the acquisition, development, and commercialization of products primarily in cardiovascular, pain management and other specialty areas. Its key products include Fiorinal, Proferrin, Fibricor, Uracyst and Neovisc, Cambia and other marketed products. The company currently operates in two geographical markets, the United States and Canada. The firm generates most of its reven


OTCPK:ARLZQ - Post by User

Post by PoorOpinionon Apr 20, 2016 8:45am
97 Views
Post# 24787724

More news out today

More news out todayI found a link with a simple explanation of the pdufa date if people were wondering what it meant

https://www.eyeonfda.com/eye_on_fda/2010/07/what-is-pdufa.html
"What is a PDUFA date?  The new system established set time periods for the FDA to review a new application, usually set at a 10-month period.  If a drug, however, gets a priority review designation, then the review time will be set at 6 months.  (A priority review is given to drugs that offer a significant new breakthrough in treatment, or offer a treatment where none or few exist, and can be given for a drug which treats a serious condition as well as those that treat less serious conditions).  The timing for the clock to tick begins when the company submits the new drug application to the FDA.  The date is a target for FDA, but the agency can, and many times does, announce a decision prior to the PDUFA date.  "
<< Previous
Bullboard Posts
Next >>